Bayer mira na oncologia em negociação de US$ 930 milhões com a Tavros
Fonte: FirstWord Pharma(Texto original, publicado em inglês) Bayer in pursuit of oncology targets via $930-million Tavros deal Bayer struck a deal to use Tavros Therapeutics’ functional genomics and computational analysis technologies in order to zero in on multiple oncology targets, the companies announced Wednesday. “Many targets remain inaccessible to traditional small-molecule drugs, and many others